Literature DB >> 2976773

Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test.

A L Barry1, P B Fernandes, J H Jorgensen, C Thornsberry, D J Hardy, R N Jones.   

Abstract

Four separate laboratories performed antimicrobial susceptibility tests with 40 Haemophilus influenzae isolates, each tested in triplicate. Erythromycin and a new macrolide, clarithromycin (A-56268; TE-031), were tested by the disk diffusion method, by the agar dilution procedure in two different media, and by broth microdilution tests in four different media. Erythromycin MICs for 90% of the strains were 16 micrograms/ml in Mueller-Hinton broth with 3% lysed horse blood and NAD, 4.0 micrograms/ml in hemophilus test medium, and 2.0 micrograms/ml in supplemented Schaedler broth or in the fastidious broth medium from Beckman Instruments, Inc. Clarithromycin MICs were generally 1 doubling dilution greater than erythromycin MICs in each of the media. Erythromycin disk tests corresponded best with MICs determined in the fastidious broth medium. In that same medium, clarithromycin MICs were about 1 doubling dilution greater than what would be expected from the results of disk tests. Because there were fewer growth failures, hemophilus test medium is recommended for microdilution tests with H. influenzae. Incubation of all tests for a full 24 h without an increased CO2 atmosphere was needed to achieve maximal precision of the tests. Interlaboratory and intralaboratory reproducibility of all tests was satisfactory.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2976773      PMCID: PMC266903          DOI: 10.1128/jcm.26.11.2415-2420.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965).

Authors:  R N Jones; A L Barry; P C Fuchs; C Thornsberry
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

2.  Evaluation of a proprietary broth medium for microdilution susceptibility testing of nutritionally fastidious bacteria.

Authors:  A L Barry; J L Cotton; R N Jones; R R Packer
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

3.  Disk diffusion and disk elution tests with A-56268 and erythromycin.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

4.  Antibiotic interaction of amoxycillin and clavulanic acid against 132 beta-lactamase positive Haemophilus isolates: a comparison with some other oral agents.

Authors:  J R Lapointe; C Lavallée
Journal:  J Antimicrob Chemother       Date:  1987-01       Impact factor: 5.790

5.  Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli.

Authors:  V Lorian; L D Sabath
Journal:  Appl Microbiol       Date:  1970-11

6.  Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae.

Authors:  J H Jorgensen; J S Redding; L A Maher; A W Howell
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

7.  Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model.

Authors:  P B Fernandes; D Hardy; R Bailer; E McDonald; J Pintar; N Ramer; R Swanson; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

8.  In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents.

Authors:  S Floyd-Reising; J A Hindler; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

9.  Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031).

Authors:  C W Hanson; R Bailer; E Gade; R A Rode; P B Fernandes
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

10.  In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors:  P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

View more
  12 in total

1.  Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents.

Authors:  M M Johnson; S L Hill; L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 2.  In vitro susceptibility testing of Haemophilus influenzae: review of new National Committee for Clinical Laboratory Standards recommendations.

Authors:  G V Doern
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

Review 3.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

4.  Susceptibility of Haemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite.

Authors:  A L Barry; P C Fuchs; M A Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

5.  Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin. Collaborative Antimicrobial Susceptibility Testing Group.

Authors:  A L Barry; C Thornsberry; T L Gavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

6.  Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH.

Authors:  A M Nilius; J M Beyer; R K Flamm; S K Tanaka
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

7.  Effect of the inoculum size on carbapenem susceptibilities of beta-lactamase-negative, ampicillin-resistant Haemophilus influenzae.

Authors:  Hiroo Miyazaki; Toshinobu Horii; Osanori Nagura; Takafumi Suda; Kingo Chida; Hirotoshi Nakamura
Journal:  Curr Microbiol       Date:  2008-09-25       Impact factor: 2.188

Review 8.  Clarithromycin clinical pharmacokinetics.

Authors:  F Fraschini; F Scaglione; G Demartini
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

9.  Broth microdilution testing of Haemophilus influenzae with haemophilus test medium versus lysed horse blood broth. Canadian Haemophilus Study Group.

Authors:  S R Scriver; D E Low; A E Simor; B Toye; A McGeer; R Jaeger
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

Review 10.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D H Peters; S P Clissold
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.